To recover your password please fill in your email address
Please fill in below form to create an account with us
A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with high-risk, metastatic (stage IV) squamous or non-squamous non-small cell lung cancer (NSCLC).
See ANZCTR for full trial details >
|
Trial Summary: |
To compare the overall survival of patients receiving durvalumab, tremelimumab plus platinum based chemotherapy to that of patients receiving durvalumab and tremelimumab alone. |
|
Supported By: |
Canadian Cancer Trial Group (CCTG), Astra Zeneca |
|
Eligibility: |
Patients with confirmed stage IV diagnosis of squamous or non-squamous, non-small cell carcinoma of the lung. |
|
Registration ID: |
ACTRN12617001468314 |
|
Participation: |
Australia & Canada |
|
Australian lead group: |
TOGA |
|
Status: |
In follow-up |
|
Activation Date: |
October 2017 |
|
Chairs: |
A/Prof Brett Hughes |
|
Contact: |